Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
Information source: National Cancer Institute (NCI)
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Breast Cancer
Intervention: carboplatin (Drug); cyclophosphamide (Drug); doxorubicin hydrochloride (Drug); filgrastim (Drug); paclitaxel (Drug); thiotepa (Drug); peripheral blood stem cell transplantation (Procedure)
Phase: Phase 2
Sponsored by: Beckman Research Institute
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: This randomized phase II trial is studying two different regimens of combination
chemotherapy and comparing them to see how well they work in treating patients with high-risk
primary stage II or stage III breast cancer.
Official title: Randomized Phase II Study of Adriamycin/Cytoxan/Taxol (ACT) vs. Cytoxan, Thiotepa, Carboplatin (STAMP V) in Patients With High-Risk Primary Breast Cancer
Study design: Treatment, Randomized, Active Control
Incidence of grade IV toxicity
Time to engraftment
Time to platelet independence
Reduction in the degree of developing osteoporosis
Incidence of novel clonal hematopoietic abnormalities
- Compare the toxic effects of doxorubicin, cyclophosphamide, and paclitaxel vs
cyclophosphamide, thiotepa, and carboplatin in patients with high-risk primary breast
cancer. (Arm I closed to accural as of 4/6/2006.)
- Compare the efficacies of these regimens followed by peripheral blood stem cell rescue
in these patients.
- Determine the efficacy of a bisphosphonate to prevent relapse/metastasis after high-dose
chemotherapy in these patients.
OUTLINE: This is a randomized study. Patients are stratified by stage of disease.
Peripheral blood stem cells (PBSC) are collected after mobilization with filgrastim (G-CSF),
administered subcutaneously or IV, twice daily beginning 3 days before collection and
continuing until collection is complete.
All patients receive conventional-dose adjuvant chemotherapy, probably comprising doxorubicin
IV, cyclophosphamide IV, and fluorouracil IV over 1 hour on days 1, 22, 43, and 64. Patients
are then randomized to receive 1 of 2 treatment arms of high-dose chemotherapy. (Arm I closed
to accrual as of 4/6/2006.)
- Arm I (ACT) (closed to accrual as of 4/6/2006): Patients receive doxorubicin IV over 24
hours on days - 9 to -6, cyclophosphamide IV over 2 hours on day -5, and paclitaxel IV
over 24 hours on day - 2. PBSC are reinfused on days -2 and 0. G-CSF is administered
beginning on day 0 and continuing until blood counts recover.
- Arm II (STAMP V): Patients receive cyclophosphamide IV, carboplatin IV, and thiotepa IV
over 24 hours on days - 7 to -4. PBSC are reinfused and G-CSF is administered as in arm
Within 4-6 weeks of day 0 of high-dose chemotherapy, patients with estrogen and/or
progesterone receptor positive tumors receive oral tamoxifen twice daily for 5 years.
Patients are also randomized to receive a bisphosphonate comprising pamidronate IV every 4
weeks for 2 years.
Quality of life is assessed before therapy, at 30 days after high-dose chemotherapy, and at 6
and 12 months.
Patients are followed every 3 months for 1 year and then every 6 months for at least 10
PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study within 3 years.
Minimum age: N/A.
Maximum age: 60 Years.
- Histologically proven high-risk primary breast cancer with less than 60% chance of
progression-free survival of 3 years from diagnosis
- Stage II with at least 10 positive axillary nodes OR
- Stage IIIA or IIIB
- No histologically proven bone marrow metastasis
- No CNS metastasis
- Hormone receptor status:
- Hormone receptor status known
- Physiological age 60 or under
- Not specified
- Karnofsky 80-100%
- See Disease Characteristics
- Neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Bilirubin no greater than 1. 5 mg/dL
- SGOT or SGPT no greater than 2 times upper limit of normal
- Hepatitis B antigen negative
- Creatinine no greater than 1. 2 mg/dL
- Creatinine clearance at least 70 mL/min
- No prior hemorrhagic cystitis
- Ejection fraction at least 55% by MUGA
- No prior significant valvular heart disease or arrhythmia
- FEV_1 at least 60% of predicted
- pO_2 at least 85 mm Hg on room air
- pCO_2 at least 43 mm Hg on room air
- DLCO at least 60% lower limit of predicted
- No other prior malignancy except squamous cell or basal cell skin cancer or stage I or
carcinoma in situ of the cervix
- No CNS dysfunction that would preclude compliance
- HIV negative
- No sensitivity to E. coli-derived products
- Not pregnant
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
- Not specified
- At least 4 weeks since prior chemotherapy
- No prior doxorubicin of total dose exceeding 240 mg/m^2
- No prior paclitaxel of total dose of at least 750 mg/m^2
- No more than 12 months since prior conventional-dose adjuvant chemotherapy
- At least 4 weeks since prior hormonal therapy
- At least 4 weeks since prior radiotherapy
- No prior radiation to the left chest wall
- Not specified
Locations and Contacts
Banner Good Samaritan Medical Center, Phoenix, Arizona 85006, United States; Recruiting
Jeffrey R. Schriber, MD, Phone: 602-239-4526, Email: email@example.com
City of Hope Comprehensive Cancer Center, Duarte, California 91010-3000, United States; Recruiting
Clinical Trials Office - City of Hope Comprehensive Cancer Cen, Phone: 800-826-4673, Email: firstname.lastname@example.org
Clinical trial summary from the National Cancer Institute's PDQ® database
Starting date: May 1999
Last updated: October 22, 2008